

Kaela E Goldstein

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4653390/publications.pdf>

Version: 2024-02-01

10
papers

433
citations

1040056

9
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

360
citing authors

#	ARTICLE	IF	CITATIONS
1	Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 479-493.	8.1	113
2	Cytokine release and gastrointestinal symptoms after gluten challenge in celiac disease. <i>Science Advances</i> , 2019, 5, eaaw7756.	10.3	84
3	Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. <i>EBioMedicine</i> , 2017, 26, 78-90.	6.1	51
4	Elevated serum interleukin-2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 901-910.	3.7	51
5	Baseline quantitative histology in therapeutics trials reveals villus atrophy in most patients with coeliac disease who appear well controlled on gluten-free diet. <i>GastroHep</i> , 2020, 2, 22-30.	0.6	43
6	Masked bolus gluten challenge low in FODMAPs implicates nausea and vomiting as key symptoms associated with immune activation in treated coeliac disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 244-252.	3.7	27
7	Cytokine release after gluten ingestion differentiates coeliac disease from self-reported gluten sensitivity. <i>United European Gastroenterology Journal</i> , 2020, 8, 108-118.	3.8	26
8	Patient factors influencing acute gluten reactions and cytokine release in treated coeliac disease. <i>BMC Medicine</i> , 2020, 18, 362.	5.5	22
9	A Sensitive Whole Blood Assay Detects Antigen-Stimulated Cytokine Release From CD4+ T Cells and Facilitates Immunomonitoring in a Phase 2 Clinical Trial of Nexvax2 in Coeliac Disease. <i>Frontiers in Immunology</i> , 2021, 12, 661622.	4.8	14
10	Sa1395 Nexvax2 [®] , a Peptide-Based Antigen-Specific Immunotherapy, Administered Intra-Dermally Three-Times Over 15-Days attenuates Responsiveness to Immuno-Dominant Gluten Peptides in HLA-DQ2.5+ People With Celiac Disease (CeD). <i>Gastroenterology</i> , 2016, 150, S304.	1.3	2